Helix BioPharma Corp. Announces Fiscal First Quarter 2018 Results RICHMOND HILL, ONTARIO--(Marketwired - Dec. 13, 2017) - Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending October 31, 2017. FINANCIAL REVIEW The Company recorded a net loss and total comprehensive loss of $2,303,000 ($0.02 loss per common share) and $3,287,000 ($0.04 loss per common share) for the three-month periods ended October 31, 2017 and 2016, respectively. Research and development Research and development costs for the three-month periods ended...
|
